Edan Gilles
Edan Gilles
University HOSPITAL of Rennes (CHU)
Adresse e-mail validée de
Citée par
Citée par
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis
WI McDonald, A Compston, G Edan, D Goodkin, HP Hartung, FD Lublin, ...
Annals of Neurology: Official Journal of the American Neurological …, 2001
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
CH Polman, SC Reingold, G Edan, M Filippi, HP Hartung, L Kappos, ...
Annals of Neurology: Official Journal of the American Neurological …, 2005
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
G Comi, M Filippi, F Barkhof, L Durelli, G Edan, O Fernández, HP Hartung, ...
The Lancet 357 (9268), 1576-1582, 2001
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity
R Roxburgh, SR Seaman, T Masterman, AE Hensiek, SJ Sawcer, ...
Neurology 64 (7), 1144-1151, 2005
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
L Kappos, CH Polman, MS Freedman, G Edan, HP Hartung, DH Miller, ...
Neurology 67 (7), 1242-1249, 2006
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ...
The Lancet 391 (10127), 1263-1273, 2018
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the …
L Kappos, MS Freedman, CH Polman, G Edan, HP Hartung, DH Miller, ...
The Lancet 370 (9585), 389-397, 2007
Evidence for a two-stage disability progression in multiple sclerosis
E Leray, J Yaouanq, E Le Page, M Coustans, D Laplaud, J Oger, G Edan
Brain 133 (7), 1900-1913, 2010
Natural history of multiple sclerosis with childhood onset
C Renoux, S Vukusic, Y Mikaeloff, G Edan, M Clanet, B Dubois, ...
New England Journal of Medicine 356 (25), 2603-2613, 2007
Vitamin D as an early predictor of multiple sclerosis activity and progression
A Ascherio, KL Munger, R White, K Köchert, KC Simon, CH Polman, ...
JAMA neurology 71 (3), 306-314, 2014
Epidemiology of multiple sclerosis
E Leray, T Moreau, A Fromont, G Edan
Revue neurologique 172 (1), 3-13, 2016
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled …
L Kappos, G Comi, H Panitch, J Oger, J Antel, P Conlon, L Steinman, ...
Nature medicine 6 (10), 1176-1182, 2000
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.
G Edan, D Miller, M Clanet, C Confavreux, O Lyon-Caen, C Lubetzki, ...
Journal of Neurology, Neurosurgery & Psychiatry 62 (2), 112-118, 1997
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 …
L Kappos, MS Freedman, CH Polman, G Edan, HP Hartung, DH Miller, ...
The Lancet Neurology 8 (11), 987-997, 2009
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring
L Kappos, D Bates, G Edan, M Eraksoy, A Garcia-Merino, N Grigoriadis, ...
The Lancet Neurology 10 (8), 745-758, 2011
Genome‐wide meta‐analysis identifies novel multiple sclerosis susceptibility loci
NA Patsopoulos, ...
Annals of neurology 70 (6), 897-912, 2011
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study
B Stankoff, E Waubant, C Confavreux, G Edan, M Debouverie, ...
Neurology 64 (7), 1139-1143, 2005
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomised, double-blind, placebo-controlled study
A Tourbah, C Lebrun-Frenay, G Edan, M Clanet, C Papeix, S Vukusic, ...
Multiple Sclerosis Journal 22 (13), 1719-1731, 2016
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab
PS Sørensen, A Bertolotto, G Edan, G Giovannoni, R Gold, E Havrdova, ...
Multiple Sclerosis Journal 18 (2), 143-152, 2012
Lack of association between antimyelin antibodies and progression to multiple sclerosis
J Kuhle, C Pohl, M Mehling, G Edan, MS Freedman, HP Hartung, ...
New England Journal of Medicine 356 (4), 371-378, 2007
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20